AstraZeneca (AZNCF) Stock Forecast & Price Target

Compare

226 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZNCF Analyst Ratings

Moderate Buy

12 Buy

2 Hold

1 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZNCF Stock 12 Month Forecast

Average Price Target

$196.30

▲(7.27% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $196.30 with a high forecast of $248.32 and a low forecast of $141.71. The average price target represents a 7.27% change from the last price of $183.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"126":"$126","249":"$249","156.75":"$156.8","187.5":"$187.5","218.25":"$218.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":248.321432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$248.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":196.2955278073,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$196.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.705165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$141.71</span>\n  </div></div>","useHTML":true}}],"tickPositions":[126,156.75,187.5,218.25,249],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.35,185.5785716923077,190.8071433846154,196.03571507692305,201.26428676923075,206.49285846153845,211.72143015384614,216.95000184615384,222.17857353846154,227.40714523076923,232.63571692307693,237.8642886153846,243.0928603076923,{"y":248.321432,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.35,181.5765790621,182.8031581242,184.0297371863,185.2563162484,186.4828953105,187.7094743726,188.9360534347,190.1626324968,191.3892115589,192.615790621,193.8423696831,195.0689487452,{"y":196.2955278073,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,180.35,177.3773203846154,174.40464076923075,171.43196115384615,168.45928153846154,165.4866019230769,162.5139223076923,159.5412426923077,156.56856307692306,153.59588346153845,150.62320384615384,147.65052423076924,144.6778446153846,{"y":141.705165,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":132.712,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.213,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.703,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.932,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.101,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.662,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.749,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.485,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.555,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":180.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$248.32

Average Price Target$196.30

Lowest Price Target$141.71

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

$141.71

Sell

-22.57%

Downside

Reiterated

12/16/25

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

Richard Vosser

J.P. Morgan

$188.94→$215.93

Buy

18.00%

Upside

Reiterated

12/08/25

JPMorgan ups AstraZeneca target, adds to Analyst Focus ListJPMorgan ups AstraZeneca target, adds to Analyst Focus List

Justin Smith

Bernstein

$248.32

Buy

35.69%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

$188.94→$209.18

Buy

14.31%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Seamus Fernandez

Guggenheim

$191.64→$209.18

Buy

14.31%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Unknown Analyst

HSBC

Not Ranked

HSBC

$146.4→$165

Buy

-9.84%

Downside

Reiterated

12/02/25

Michael Leuchten

Jefferies

$202.44

Buy

10.62%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

$195.69→$222.68

Buy

21.68%

Upside

Reiterated

11/25/25

AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation

Luisa Hector

Berenberg Bank

$195.69

Buy

6.93%

Upside

Reiterated

11/11/25

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Matthew Weston

UBS

$191.64

Buy

4.72%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

$204.64→$209.24

Buy

14.34%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

$195.69

Buy

6.93%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

$152.5

Hold

-16.67%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

$188.94

Buy

3.25%

Upside

Reiterated

10/21/25

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

$141.71

Sell

-22.57%

Downside

Reiterated

12/16/25

AstraZeneca (AZN) Gets a Sell from Deutsche Bank

Richard Vosser

J.P. Morgan

$188.94→$215.93

Buy

18.00%

Upside

Reiterated

12/08/25

JPMorgan ups AstraZeneca target, adds to Analyst Focus ListJPMorgan ups AstraZeneca target, adds to Analyst Focus List

Justin Smith

Bernstein

$248.32

Buy

35.69%

Upside

Reiterated

12/04/25

Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)

Sarita Kapila

Morgan Stanley

$188.94→$209.18

Buy

14.31%

Upside

Reiterated

12/03/25

AstraZeneca: Top Pick in a Growing Pharmaceutical Sector with Promising Pipeline and Resolved Overhangs

Seamus Fernandez

Guggenheim

$191.64→$209.18

Buy

14.31%

Upside

Reiterated

12/02/25

AstraZeneca (AZN) Receives a Rating Update from a Top Analyst

Unknown Analyst

HSBC

Not Ranked

HSBC

$146.4→$165

Buy

-9.84%

Downside

Reiterated

12/02/25

Michael Leuchten

Jefferies

$202.44

Buy

10.62%

Upside

Reiterated

12/01/25

AstraZeneca (AZN) Receives a Buy from Jefferies

Sachin Jain

Bank of America Securities

$195.69→$222.68

Buy

21.68%

Upside

Reiterated

11/25/25

AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation

Luisa Hector

Berenberg Bank

$195.69

Buy

6.93%

Upside

Reiterated

11/11/25

Berenberg Bank Keeps Their Buy Rating on AstraZeneca (AZN)

Elmar Kraus

DZ BANK AG

Hold

―

Reiterated

11/10/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Matthew Weston

UBS

$191.64

Buy

4.72%

Upside

Reiterated

11/07/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Rajan Sharma

Goldman Sachs

$204.64→$209.24

Buy

14.34%

Upside

Reiterated

11/07/25

AstraZeneca (AZN) Gets a Buy from Goldman Sachs

Unknown Analyst

Shore Capital

Not Ranked

Shore Capital

$195.69

Buy

6.93%

Upside

Reiterated

11/06/25

Shore Capital Reaffirms Their Buy Rating on AstraZeneca (AZN)

David Evans

Kepler Capital

$152.5

Hold

-16.67%

Downside

Reiterated

10/22/25

Kepler Capital Sticks to Its Hold Rating for AstraZeneca (AZN)

Shirley Chen

Barclays

$188.94

Buy

3.25%

Upside

Reiterated

10/21/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+0.90%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +0.90% per trade.

3 Months

xxx

Success Rate

14/20 ratings generated profit

Average Return

+3.25%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +3.25% per trade.

1 Year

Matthew WestonUBS

Success Rate

35/37 ratings generated profit

Average Return

+17.26%

reiterated a buy rating 2 months ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.59% of your transactions generating a profit, with an average return of +17.26% per trade.

2 Years

xxx

Success Rate

19/20 ratings generated profit

Average Return

+24.52%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 95.00% of your transactions generating a profit, with an average return of +24.52% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZNCF Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZNCF has received 35 Buy Ratings, 2 Hold Ratings, and 6 Sell Ratings. AZNCF average Analyst price target in the past 3 months is 196.30.

Each month's total comprises the sum of three months' worth of ratings.

AZNCF Financial Forecast

AZNCF Earnings Forecast

Next quarter’s earnings estimate for AZNCF is $2.12 with a range of $1.90 to $2.36. The previous quarter’s EPS was $2.38. AZNCF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AZNCF has Performed in-line its overall industry.

AZNCF Sales Forecast

Next quarter’s sales forecast for AZNCF is $15.42B with a range of $15.01B to $15.90B. The previous quarter’s sales results were $15.19B. AZNCF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AZNCF has Performed in-line its overall industry.

AZNCF Stock Forecast FAQ

What is AZNCF’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 196.30.

What is AZNCF’s upside potential, based on the analysts’ average price target?

AstraZeneca PLC has 7.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AZNCF a Buy, Sell or Hold?

AstraZeneca PLC has a consensus rating of Moderate Buy which is based on 12 buy ratings, 2 hold ratings and 1 sell ratings.

What is AstraZeneca PLC’s price target?

The average price target for AstraZeneca PLC is 196.30. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $248.32 ,the lowest forecast is $141.71. The average price target represents 7.27% Increase from the current price of $183.

What do analysts say about AstraZeneca PLC?

AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AZNCF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

AstraZeneca (AZNCF) Stock Forecast & Price Target

AZNCF Analyst Ratings

AZNCF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZNCF Analyst Recommendation Trends

AZNCF Financial Forecast

AZNCF Earnings Forecast

AZNCF Sales Forecast

AZNCF Stock Forecast FAQ

Detailed List of Analyst Forecasts